
    
      This is a Phase 2a, multi-center, double-blind, placebo-controlled study evaluating
      ABI-H0731+ ETV vs ETV alone for the treatment of viremic hepatitis B "e" antigen
      (HBeAg)-positive participants with cHBV.
    
  